Patient demographics, TNM stages, and therapya
| Demographics and Staging | |
|---|---|
| Age (yr) | |
| Median | 61 |
| Range | 21–89 |
| Sex | |
| Male | 388 (76%) |
| Female | 124 (24%) |
| Site of origin (n = 419) | |
| Oropharynx | 130 (31%) |
| Oral cavity | 130 (31%) |
| Larynx | 63 (15%) |
| Maxillofacial/sinus | 37 (9%) |
| Hypopharynx | 26 (6%) |
| Nasopharynx | 12 (3%) |
| Trans-spatial | 10 (2%) |
| Unknown primary | 8 (2%) |
| T stage (n = 428) | |
| T0 | 9 (2%) |
| T1 | 109 (25%) |
| T2 | 124 (29%) |
| T3 | 85 (20%) |
| T4 | 101 (24%) |
| N stage (n = 440) | |
| N0 | 192 (44%) |
| N1 | 69 (16%) |
| N2 | 162 (37%) |
| N3 | 17 (4%) |
| M stage (n = 369) | |
| M0 | 365 (99%) |
| M1 | 4 (1%) |
| Therapy (n = 512) | |
| CRT alone | 67 (13%) |
| Surgery plus CRT | 445 (87%) |
Note:—CRT indicates chemoradiation therapy; N, node; M, metastasis.
↵a A total of 512 patients were included in this study, but not all patients had initial staging data available, so fewer patients are included. The number of patients with available data is listed in the header for each section.